Comparable stake leader
BlackRock, Inc.
SEC ownership of AVADEL PHARMACEUTICALS PLC
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001012477.
Disclosed value leader
BlackRock, Inc.
Comparable rows
6/10
Latest evidence
30 Jun 2026
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
6 of 10
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001012477
- Issuer location
- Dublin 2
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of AVADEL PHARMACEUTICALS PLC (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
6/10
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 7%
4 rows are not safely comparable across share classes.
13D/G row: BlackRock, Inc.
Showing 1-8 of 10 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 7%.
6 of 10 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
7%
VANGUARD GROUP INC
5.7%
Jeffrey L. Gendell
4.9%
Janus Henderson Group Ltd.
1.9%
BRANDES INVESTMENT PARTNERS, LP
0.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 10 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13D/G
|
7%
|
$59,674,993
6,742,480 shares
|
$0 | 30 Jun 2025 |
| VANGUARD GROUP INC |
13D/G
The Vanguard Group
|
5.7%
|
$49,243,692
5,564,259 shares
|
$0 | 30 Jun 2025 |
| Jeffrey L. Gendell |
13D/G
|
4.9%
|
—
4,839,357 shares
|
$0 | 31 Dec 2025 |
| Janus Henderson Group Ltd. |
13D/G
JANUS HENDERSON GROUP PLC
|
1.9%
|
$39,176,620
1,823,865 shares
|
-$120,413,722 | 31 Dec 2025 |
| BRANDES INVESTMENT PARTNERS, LP |
13D/G
|
0.2%
|
$4,700,576
218,835 shares
|
-$117,105,674 | 31 Dec 2025 |
| HUNTINGTON NATIONAL BANK |
13F
Company
|
0%
|
$16
1 shares
|
— | 30 Jun 2026 |
| Geoffrey Michael Glass |
3/4/5
Director
|
— |
$140,250
|
— | 12 Feb 2026 |
| Linda Palczuk |
3/4/5
Director
|
— |
$140,250
|
— | 12 Feb 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$233,353,092.
Buys
$0
Insiders: 0
Sells
$233,353,092
Insiders: 1
Net
-$233,353,092
Shares: -11,112,052
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 11,112,052
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 11,112,052 | $0 | $233,353,092 | -$233,353,092 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to AVADEL PHARMACEUTICALS PLC. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Geoffrey Michael Glass
Net 12M change
-$233,353,092
Latest report
13 Feb 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Geoffrey Michael Glass | Director | $140,250 | Mixed | 12 Feb 2026 | ||
| Linda Palczuk | Director | $140,250 | Mixed | 12 Feb 2026 | ||
| Gregory J. Divis | Chief Executive Officer, Director | $0 | Mixed | 12 Feb 2026 | ||
| Naseem Amin | Director | $0 | Mixed | 12 Feb 2026 | ||
| Jerad G. Seurer | Gen. Counsel & Corp. Secretary | $0 | Mixed | 12 Feb 2026 | ||
| Thomas S. Mchugh | Chief Financial Officer | $0 | Mixed | 12 Feb 2026 | ||
| Mark Anthony McCamish | Director | $0 | Mixed | 12 Feb 2026 | ||
| Peter J. Thornton | Director | $0 | Mixed | 12 Feb 2026 | ||
| Weiss Asset Management LP | Former 10% Owner | $0 | -$233,353,092 | -100% | Mixed | 13 Feb 2026 |
| Eric J. Ende | Director | $0 | Mixed | 12 Feb 2026 | ||
| Susan Rodriguez | Chief Operating Officer | Mixed | 12 Feb 2026 | |||
| Douglas J. Williamson | Chief Medical Officer | Mixed | 14 Feb 2022 | |||
| Richard J. Kim | Chief Commercial Officer | Mixed | 20 Feb 2024 |
Recent insider transactions for AVADEL PHARMACEUTICALS PLC
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Weiss Asset Management LP | AVDL | Ordinary Shares | Sale | -100% | $233,353,092 | $21.00 | -11,112,052 | 0 | 13 Feb 2026 | See Footnote 2 |
| Susan Rodriguez | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -300,000 | 0 | 12 Feb 2026 | Direct | ||
| Peter J. Thornton | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -115,060 | 0 | 12 Feb 2026 | Direct | ||
| Peter J. Thornton | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -241,000 | 0 | 12 Feb 2026 | Direct | ||
| Jerad G. Seurer | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -23,496 | 0 | 12 Feb 2026 | Direct | ||
| Jerad G. Seurer | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -491,500 | 0 | 12 Feb 2026 | Direct | ||
| Linda Palczuk | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -78,905 | 0 | 12 Feb 2026 | Direct | ||
| Linda Palczuk | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -266,000 | 0 | 12 Feb 2026 | By Trust | ||
| Thomas S. Mchugh | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -100,400 | 0 | 12 Feb 2026 | Direct | ||
| Thomas S. Mchugh | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -1,004,500 | 0 | 12 Feb 2026 | Direct | ||
| Mark Anthony McCamish | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -67,025 | 0 | 12 Feb 2026 | By McCamish Charitable Remainder Trust | ||
| Mark Anthony McCamish | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -22,000 | 0 | 12 Feb 2026 | Direct | ||
| Mark Anthony McCamish | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -291,000 | 0 | 12 Feb 2026 | Direct | ||
| Geoffrey Michael Glass | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -144,979 | 0 | 12 Feb 2026 | By Trust | ||
| Geoffrey Michael Glass | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -22,005 | 0 | 12 Feb 2026 | Direct | ||
| Geoffrey Michael Glass | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -241,000 | 0 | 12 Feb 2026 | By Trust | ||
| Eric J. Ende | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -219,905 | 0 | 12 Feb 2026 | Direct | ||
| Eric J. Ende | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -249,057 | 0 | 12 Feb 2026 | Direct | ||
| Gregory J. Divis | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -10,000 | 0 | 12 Feb 2026 | By Trust | ||
| Gregory J. Divis | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -211,105 | 0 | 12 Feb 2026 | Direct | ||
| Gregory J. Divis | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -2,870,000 | 0 | 12 Feb 2026 | Direct | ||
| Naseem Amin | AVDL | Ordinary Shares | Disposed to Issuer | -100% | -22,000 | 0 | 12 Feb 2026 | Direct | ||
| Naseem Amin | AVDL | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -71,500 | 0 | 12 Feb 2026 | Direct | ||
| Mark Anthony McCamish | AVDL | Ordinary Shares | Gift | 67,025 | 67,025 | 04 Feb 2026 | By McCamish Charitable Remainder Trust | |||
| Mark Anthony McCamish | AVDL | Ordinary Shares | Gift | -100% | -67,025 | 0 | 04 Feb 2026 | By Matthew 5 LLC | ||
| Linda Palczuk | AVDL | Stock Option (Right to Buy) | Gift | -100% | -11,000 | 0 | 15 Sep 2025 | Direct | ||
| Geoffrey Michael Glass | AVDL | Stock Option (Right to Buy) | Gift | -100% | -11,000 | 0 | 15 Sep 2025 | Direct |
* marks a reported price that did not pass the local price check.